Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
GSN	P06396	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
GSN	P06396	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
GSN	P06396	Katzeff et al. 2020	ALS – Control	Serum	Down	28 ALS, 22 control		52.7
GRIA4	P48058	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GRHPR	Q9UBQ7	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GRB2	P62993	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GPX4	K7ERP4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GPX4	P36969	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
GPX2	P18283	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
GPR56	Q9Y653	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
GPR56	Q9Y653	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GPR37L1	O60883	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GPR126	Q86SQ4	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
GPNMB	Q14956	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
GPNMB	Q14956	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
GPNMB	Q14956	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
GPNMB	Q14956	Oh et al. 2023	ALS – Control	CSF	Up	20 ALS, 20 control		59
GPNMB	Q14956	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
GPNMB	Q14956	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Up	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GPM6A	P51674	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GPLD1	P80108	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
GPLD1	P80108	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GPIHBP1	Q8IV16	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
GPI	P06744	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GPD1L	Q8N335	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GPC4	O75487	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GPC1	P35052	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GP1BA	P07359	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
GP1BA	P07359	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GOT2	P00505	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
GOT2	P00505	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GOT2	P00505	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GOT2	P00505	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
GOT2	P00505	Zubiri et al. 2018	Late ALS – Early ALS (ALS fast cohort)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
GOT1	P17174	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GOT1	P17174	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
GOT1	P17174	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
GOT1	P17174	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GOLM1	Q8NBJ4	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
GOLGA2	Q08379	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
GNRH1	P01148	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GNPDA2	Q8TDQ7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GNG7	O60262	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GNG5	P63218	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GNG3	P63215	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
GNAO1	P09471	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GNAI2	P04899	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GNAI2	P04899	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
GMFG	M0QYG8	Leoni et al. 2019	BO-ALS – LO-ALS	PBMCs	Down	12 BO-ALS, 12 LO-ALS	(39-76) (BO-ALS), (33-81) (LO-ALS)
GMFB	P60983	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GM2A	P17900	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GM2A	P17900	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
GLUD1	P00367	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
GLTP	Q9NZD2	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GLRX	P35754	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GLOD4	Q9HC38	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
GLOD4	Q9HC38	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GLO1	Q04760	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GLO1	Q04760	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GLDN	Q6ZMI3	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GJA9	P57773	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
GIT1	A0A0C4DGN6	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
GHR	P10912	Berrone et al. 2023	ALS – Control	Plasma	Down	16 ALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
GHR	P10912	Berrone et al. 2023	sALS – Control	Plasma	Down	8 sALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
GGT7	Q9UJ14	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
GGT5	P36269	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
GGT5	P36269	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
GGT5	P36269	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GGCT	O75223	Englen-Lee et al. 2017	ALS – Control	Spinal cord (PH & AH)	Up	10 ALS, 10 control	57.6 ± 10.9	62.6 ± 10.6
GFRA3	O60609	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GFRA2	O00451	Vu et al. 2023	ALS fast – ALS slow	CSF	Down	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
GFAP	P14136	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
GFAP	P14136	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Up	3 ALS, 3 control		69.3	9.2
GET4	C9JPA8	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
GDI2	P50395	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GDI1	P31150	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GDAP1L1	Q96MZ0	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
GDA	Q9Y2T3	Bereman et al. 2018	ALS – Control	CSF	Down	33 ALS, 30 control
GC	P02774	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
GC	D6RF35	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GBP1	P32455	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
GBA	P04062	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GAS2	O43903	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
GAPDH	P04406	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GAP43	P17677	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
GAP43	P17677	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GANAB	Q14697	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GANAB	Q14697	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
GANAB	Q14697	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
GANAB	Q14697	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
GALNT7	Q86SF2	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GALNT16	Q8N428	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GALNT15	Q8N3T1	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GALNT15	Q8N3T1	Zhou et al. 2023	SO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
GALNT15	Q8N3T1	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
GALNT15	Q8N3T1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GALNT1	Q10472	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
GALK2	Q01415	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
GAL3ST4	Q96RP7	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
GAL3ST4	Q96RP7	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control